Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma

June 12th 2021

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

Rusfertide Eliminates Need for Phlebotomy, Reverses Iron Deficiency in Polycythemia Vera

June 12th 2021

Rusfertide has been shown to be an effective option for patients with polycythemia vera in that it reverses iron deficiency, improves disease-related symptoms, and eliminates the need for therapeutic phlebotomy.

Luspatercept Achieves Impressive Hemoglobin Increase in Non-Transfusion–Dependent Beta-Thalassemia

June 11th 2021

Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval during weeks 13 to 24 in the absence of red blood cell transfusions vs 0% with placebo in patients with non-transfusion–dependent β-thalassemia.

Dr. Wang on the Potential Impact of Menin Inhibitors in AML

June 11th 2021

Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.

Dr. Shah on Results Seen With Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

June 11th 2021

Bijal Shah, MD, MS, discusses the results seen with brexucabtagne autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as demonstrated in the phase 2 ZUMA-3 trial.

Zandelisib/Zanubrutinib Yields Promising Responses in R/R CLL, and B-cell Malignancies

June 11th 2021

A 60 mg dose of zandelisib administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Shah Spotlights the Potential Benefit of Brexucabtagene Autoleucel in Relapsed/Refractory B-Cell ALL, and Beyond

June 11th 2021

Bijal Shah, MD, MS, discusses the key findings of the ZUMA-3 trial, as well as key safety information regarding brexucabtagene autoleucel as a treatment for patients with heavily pretreated patients with relapsed/refractory B-cell ALL.

ALLO-501A With ALLO-647 Lymphodepletion Shows Early Efficacy in Relapsed/Refractory Large B-Cell Lymphoma

June 11th 2021

Treatment with the allogeneic CAR T-cell product ALLO-501A elicited encouraging signals of clinical activity when used with ALLO-647 lymphodepletion in patients with relapsed/refractory large B-cell lymphoma who did not previously receive autologous CAR T-cell therapy.

Allo-Transplant Recommended for Eligible Patients With Myelofibrosis

June 10th 2021

Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.

FDA Extends Review Period for Ruxolitinib in Chronic GVHD

June 9th 2021

The FDA has extended the review period for the supplemental new drug application for ruxolitinib as a therapeutic option for adult and pediatric patients aged 12 years and older with steroid-refractory chronic graft-versus-host disease.

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

June 8th 2021

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

June 8th 2021

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma

June 7th 2021

Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.

Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies

June 7th 2021

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL

June 7th 2021

Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.

FDA Expands Approval of Ravulizumab-cwvz in Paroxysmal Nocturnal Hemoglobinuria to Include Pediatric Patients

June 7th 2021

The FDA has approved the expanded use of ravulizumab-cwvz (Ultomiris) to include children aged 1 month and older, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers

June 7th 2021

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Targeting CLL1-Positive Cells Shows Efficacy in Early Trial in Pediatric AML

June 6th 2021

Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia.

Tafasitamab/Lenalidomide Combo Induces Durable Response in DLBCL

June 6th 2021

Three-year follow-up data from the phase 2 L-MIND study demonstrated that tafasitamab-cxix in combination with lenalidomide induces sustainable response in relapsed/refractory diffuse large B-cell lymphoma.

Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

June 6th 2021

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.